- Home
- DXPE vs BEAM Comparison
DXPE vs BEAM Comparison
Compare DXPE & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXPE
- BEAM
- Stock Information
- Founded
- DXPE 1908
- BEAM 2017
- Country
- DXPE United States
- BEAM United States
- Employees
- DXPE N/A
- BEAM N/A
- Industry
- DXPE Industrial Machinery/Components
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DXPE Industrials
- BEAM Health Care
- Exchange
- DXPE Nasdaq
- BEAM Nasdaq
- Market Cap
- DXPE 1.9B
- BEAM 1.7B
- IPO Year
- DXPE 1996
- BEAM 2020
- Fundamental
- Price
- DXPE $118.46
- BEAM $25.23
- Analyst Decision
- DXPE Buy
- BEAM Strong Buy
- Analyst Count
- DXPE 1
- BEAM 10
- Target Price
- DXPE $95.00
- BEAM $49.78
- AVG Volume (30 Days)
- DXPE 181.3K
- BEAM 2.4M
- Earning Date
- DXPE 11-03-2025
- BEAM 11-04-2025
- Dividend Yield
- DXPE N/A
- BEAM N/A
- EPS Growth
- DXPE 47.94
- BEAM N/A
- EPS
- DXPE 5.24
- BEAM N/A
- Revenue
- DXPE $1,919,100,000.00
- BEAM $60,272,000.00
- Revenue This Year
- DXPE $11.37
- BEAM N/A
- Revenue Next Year
- DXPE $4.63
- BEAM $18.95
- P/E Ratio
- DXPE $22.68
- BEAM N/A
- Revenue Growth
- DXPE 13.93
- BEAM N/A
- 52 Week Low
- DXPE $48.45
- BEAM $13.53
- 52 Week High
- DXPE $130.97
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- DXPE 50.14
- BEAM 65.07
- Support Level
- DXPE $116.22
- BEAM $22.53
- Resistance Level
- DXPE $130.84
- BEAM $26.48
- Average True Range (ATR)
- DXPE 5.53
- BEAM 1.32
- MACD
- DXPE 0.38
- BEAM 0.07
- Stochastic Oscillator
- DXPE 36.33
- BEAM 68.35
About DXPE DXP Enterprises Inc.
DXP Enterprises Inc is a distributor of products and services to industrial customers in the United States, Canada, Mexico, and Dubai. The company's reportable segments include Service Centers, Innovative Pumping Solutions, and Supply Chain Services. It generates maximum revenue from the Service Centers segment. The company offers pumping solutions, supply chain services and maintenance, repair, operating, and production services for rotating equipment, bearings, power transmissions, industrial supplies, and safety products. It serves the General Industrial, Oil & Gas, Food & Beverage, Water & Wastewater, Chemical, Transportation, Aerospace & Others.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.